CDA | Evidence Driven
CDA | Evidence Driven

Revlimid (in combo) bortezomib + dexamethasone for newly diagnosed Multiple Myeloma – Details

Details

Files
Generic Name:
Lenalidomide
Project Status:
Complete
Therapeutic Area:
Multiple Myeloma (+bortezomib+dex)
Manufacturer:
Celgene Inc.
Brand Name:
Revlimid
Project Line:
Reimbursement Review
Project Number:
PC0141-000
NOC Status at Filing:
Pre NOC
Performance Metric:
Achieved
Strength:
2.5 mg, 5 mg, 10 mg, 15 mg, 20 mg and 25 mg
Tumour Type:
Myeloma
Indications:
Multiple Myeloma
Funding Request:
The combination of lenalidomide, bortezomib, and low-dose dexamethasone, for the treatment of newly diagnosed multiple myeloma patients in whom stem cell transplantation is not intended
Sponsor:
Celgene Inc.
Submission Deemed Complete:
Submission Date (Target Date):
Stakeholder Input Deadline ‡:
Check-point meeting:
pERC Meeting:
Initial Recommendation Issued:
Feedback Deadline ‡:
Notification to Implement Issued:
Recommendation Type:
Reimburse with clinical criteria and/or conditions
pERC Meeting:
Final Recommendation Issued:

Files

Provincial Funding Summary View PDF
Lenalidomide (Revlimid) bortezomib + dexamethasone for newly diagnosed MM – pERC Final Recommendation Final Recommendation June 19, 2019 View PDF
Lenalidomide (Revlimid) bortezomib + dexamethasone for newly diagnosed MM – Final Economic Guidance Report Guidance Reports June 19, 2019 View PDF
Lenalidomide (Revlimid) bortezomib + dexamethasone for newly diagnosed MM – Final Clinical Guidance Report Guidance Reports June 19, 2019 View PDF
Lenalidomide (Revlimid) bortezomib + dexamethasone for newly diagnosed MM – pERC Initial Recommendation Initial Recommendation May 31, 2019 View PDF
Lenalidomide (Revlimid) bortezomib + dexamethasone for newly diagnosed MM – PAG Feedback on Initial Recommendation Feedback June 19, 2019 View PDF
Lenalidomide (Revlimid) bortezomib + dexamethasone for newly diagnosed MM – Manufacturer Feedback on Initial Recommendation Feedback June 19, 2019 View PDF
Lenalidomide (Revlimid) bortezomib + dexamethasone for newly diagnosed MM – Clinician Feedback on Initial Recommendation Feedback June 19, 2019 View PDF
Lenalidomide (Revlimid) bortezomib + dexamethasone for newly diagnosed MM – Patient Advocacy Group COI Declarations COI Declarations June 19, 2019 View PDF
Lenalidomide (Revlimid) bortezomib + dexamethasone for newly diagnosed MM – Clinician COI Declarations COI Declarations June 19, 2019 View PDF

‡ Patient Advocacy Groups (or individual patients and caregivers when there is no patient group) and Clinicians who are registered with pCODR are eligible to provide Input and Feedback. Deadlines for Input and Feedback are by the end of the pCODR business day (5P.M. Eastern Time) of the date noted.

Last Updated : July 5, 2019